In the past, few companies have invested in chronic and recurrent acute pancreatitis therapies, in part because researchers did not know what was causing the inflammation of the pancreas. Now, scientists are learning more about what causes the inflammation in many patients.  When we know what biological processes are going wrong (called “targets”), researchers can work to identify therapies that will correct the problem.